The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.
Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.
Results from a Phase III trial presented at ASCO suggest a significant overall survival increase by adding ribociclib to endocrine therapy in HR-positive, HER2-negative breast cancer.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
